

Are you an individual with a new diagnosis of early-stage (I-III) colorectal cancer?

Researchers at the University of Calgary are conducting a study to understand the experiences of participants when it comes to colorectal cancer treatment and management of adverse effects associated with cancer treatment strategies. Participation in this study is completely voluntary and you are free to change your mind at any time.

Who is eligible?

You are an individual newly diagnosed with early-stage (I-III) colorectal cancer who plans to seek treatment (surgery, chemotherapy, radiation therapy).

What will you be asked to do?

Early-stage cancer patients will be asked to

- 1) Provide four fecal samples over the course of a one-year period
- 2) Complete questionnaires related to participant demographics and patient reported outcomes
- 3) Give consent for research team member to access electronic medical records for the purpose of determining clinical data on tumor characteristics, treatments, and treatment toxicities

What are the benefits of participating in this study?

Your information may improve the treatment experience for future colorectal cancer patients.

If you would like more information, please contact:

Dr. Colleen Cuthbert, NP, PhD

Email: cacuthbe@ucalgary.ca

Study Title: Investigating the Effects of Cancer Treatment on Gut Microbiota in Colorectal Cancer Patients

This study has received ethical approval through the Health Research Ethics Board of Alberta, HREBA.CC-21-0153

Ethics ID: HREBA.CC-21-0153

Study Title: Investigating the Effects of Cancer Treatment on Gut Microbiota in Colorectal Cancer Patients

PI: Dr Colleen Cuthbert

Version 2021-April

Page 1 of 1